Search
CELL BANK Website

Back Back
Cell No. : Cell Name
RCB5664 : Y-MESO-8A  update : 2025/01/30
CommentRCB5664 Y-MESO-8A, RCB5665 Y-MESO-8D were derived from the same patient.
Comment from the depositorHuman pleural mesothelioma cell line. The primary tumor is a biphasic (predominantly sarcomatoid) tumor tissue. Subcloned from patient's pleural fluid and shows epithelioid morphology.
Terms and conditionsIn publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature (Cancer Sci 2006 97:387-394) designated by the DEPOSITOR is requested.
Remarks
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
Basic information Depositor SEKIDO, Yoshitaka
Originator SEKIDO, Yoshitaka
Year of deposit 2022
Original cell Y-MESO-8
Cloning (depositor) Yes
_Date (depositor) 2001
_Method (depositor) ring cloning
Animal _human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Male
Age at sampling 61 years
Tissue pleural effusion
Primary focus pleural mesothelioma
Disease name pleural mesothelioma
Tumor pleural mesothelioma (biphasic (predominantly sarcomatoid)
Metastatic ability Unknown
Classification cancer
Recombinant non-recombinant
Year of origin 2001
Lifespan infinite
Morphology epithelial-like
Cellosaurus(Expasy) CVCL_5188
deposit info
lot info
Medium Medium List
Culture type Adherent cells Adherent cells
Culture medium RPMI1640 + 10% FBS RPMI1640 + 10% FBS
Antibiotics 1% antimicrobial Free
Passage method 0.25w/v% Trypsin + 1mmol/l EDTA（FUJIFILM 209-16941） 0.25% Trypsin + (0.02% EDTA or 0.04% EDTA)
Culture information Passage ratio 1 : 5-8 split 1 : 5-8 split
SC frequency Subculture : 1-2 times/week Subculture : 1-2 times/week
Temperature 37 ℃ 37 ℃
CO2 concentration 5 % 5 %
Freeze medium CELLBANKER CELLBANKER 1
Freezing method Slow freezing
Mycoplasma/Acholeplasma (-)
Mycoplasma (-)
Animal PCR OK
Virus (HIV) (-) Undetected
Virus (HTLV-1) (-)
Virus (HBV) (-)
Virus (HCV) (-)
Virus (EBV) (-)
STR(human) OK
deposit info
D5S818 D13S317 D7S820 D16S539 vWA TH01 Amelogenin TPOX CSF1PO
11,12 8,9 11 12 14,16 7,9 X,Y 11 11,12
lot info
D5S818 D13S317 D7S820 D16S539 vWA TH01 Amelogenin TPOX CSF1PO
11,12 8,9 11 12 14,16 7,9 X,Y 11 11,12
Reference information Reference 15
User's Publication 0


To topTop
Reference
16452  Okazaki Y, Misawa N, Akatsuka S, Kohyama N, Sekido Y, Takahashi T, Toyokuni S.  Frequent homozygous deletion of Cdkn2a/2b in tremolite-induced malignant mesothelioma in rats  Cancer Sci  2020  111(4):1180-1192.  PubMed ID: 32080953   DOI: 10.1111/cas.14358
16453  Ohara Y, Chew SH, Misawa N, Wang S, Somiya D, Nakamura K, Kajiyama H, Kikkawa F, Tsuyuki Y, Jiang L, Yamashita K, Sekido Y, Lipson KE, Toyokuni S.  Connective tissue growth factor-specific monoclonal antibody inhibits growth of malignant mesothelioma in an orthotopic mouse model  Oncotarget  2018  9(26):18494-18509  PubMed ID: 29719620   DOI: 10.18632/oncotarget.24892
16454  Chew SH, Okazaki Y, Akatsuka S, Wang S, Jiang L, Ohara Y, Ito F, Saya H, Sekido Y, Toyokuni S.  Rheostatic CD44 isoform expression and its association with oxidative stress in human malignant mesothelioma  Free Radic Biol Med  2017  106:91-99  PubMed ID: 28185919   DOI: 10.1016/j.freeradbiomed.2017.02.011
16459  Wang S, Jiang L, Han Y, Chew SH, Ohara Y, Akatsuka S, Weng L, Kawaguchi K, Fukui T, Sekido Y, Yokoi K, Toyokuni S.  Urokinase-type plasminogen activator receptor promotes proliferation and invasion with reduced cisplatin sensitivity in malignant mesothelioma  Oncotarget  2016  ;7(43):69565-69578  PubMed ID: 27602956   DOI: 10.18632/oncotarget.11829
16460  Li Q, Wang W, Machino Y, Yamada T, Kita K, Oshima M, Sekido Y, Tsuchiya M, Suzuki Y, Nan-Ya K, Iida S, Nakamura K, Iwakiri S, Itoi K, Yano S.  Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma  Cancer Sci  2015  106(1):102-7  PubMed ID: 25421609   DOI: 10.1111/cas.12575
16455  Chew SH, Okazaki Y, Nagai H, Misawa N, Akatsuka S, Yamashita K, Jiang L, Yamashita Y, Noguchi M, Hosoda K, Sekido Y, Takahashi T, Toyokuni S.  Cancer-promoting role of adipocytes in asbestos-induced mesothelial carcinogenesis through dysregulated adipocytokine production  Carcinogenesis  2014  35(1):164-72  PubMed ID: 23917077   DOI: 10.1093/carcin/bgt267
16461  Abe S, Morita Y, Kaneko MK, Hanibuchi M, Tsujimoto Y, Goto H, Kakiuchi S, Aono Y, Huang J, Sato S, Kishuku M, Taniguchi Y, Azuma M, Kawazoe K, Sekido Y, Yano S, Akiyama S, Sone S, Minakuchi K, Kato Y, Nishioka Y.  A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody  J Immunol  2013  190(12):6239-49  PubMed ID: 23690472   DOI: 10.4049/jimmunol.1300448
16462  Satoh M, Takemura Y, Hamada H, Sekido Y, Kubota S.  EGCG induces human mesothelioma cell death by inducing reactive oxygen species and autophagy  Cancer Cell Int  2013  13(1):19  PubMed ID: 23432995   DOI: 10.1186/1475-2867-13-19
16456  Horio M, Sato M, Takeyama Y, Elshazley M, Yamashita R, Hase T, Yoshida K, Usami N, Yokoi K, Sekido Y, Kondo M, Toyokuni S, Gazdar AF, Minna JD, Hasegawa Y.  Transient but not stable ZEB1 knockdown dramatically inhibits growth of malignant pleural mesothelioma cells  Ann Surg Oncol  2012  19 Suppl 3(Suppl 3):S634-45  PubMed ID: 22086445   DOI: 10.1245/s10434-011-2142-0
16463  Takemura Y, Satoh M, Satoh K, Hamada H, Sekido Y, Kubota S.  High dose of ascorbic acid induces cell death in mesothelioma cells  Biochem Biophys Res Commun  2010  394(2):249-53  PubMed ID: 20171954   DOI: 10.1016/j.bbrc.2010.02.012
16457  Suzuki Y, Murakami H, Kawaguchi K, Tanigushi T, Fujii M, Shinjo K, Kondo Y, Osada H, Shimokata K, Horio Y, Hasegawa Y, Hida T, Sekido Y.  Activation of the PI3K-AKT pathway in human malignant mesothelioma cells  Mol Med Rep  2009  2(2):181-8  PubMed ID: 21475810   DOI: 10.3892/mmr_00000081
16464  Goto Y, Shinjo K, Kondo Y, Shen L, Toyota M, Suzuki H, Gao W, An B, Fujii M, Murakami H, Osada H, Taniguchi T, Usami N, Kondo M, Hasegawa Y, Shimokata K, Matsuo K, Hida T, Fujimoto N, Kishimoto T, Issa JP, Sekido Y.  Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma  Cancer Res  2009  69(23):9073-82  PubMed ID: 19887624   DOI: 10.1158/0008-5472.CAN-09-1595
16465  Yamada T, Yano S, Ogino H, Ikuta K, Kakiuchi S, Hanibuchi M, Kanematsu T, Taniguchi T, Sekido Y, Sone S.  Lysophosphatidic acid stimulates the proliferation and motility of malignant pleural mesothelioma cells through lysophosphatidic acid receptors, LPA1 and LPA2  Cancer Sci  2008  99(8):1603-10  PubMed ID: 18754873   DOI: 10.1111/j.1349-7006.2008.00848.x
16458  Taniguchi T, Karnan S, Fukui T, Yokoyama T, Tagawa H, Yokoi K, Ueda Y, Mitsudomi T, Horio Y, Hida T, Yatabe Y, Seto M, Sekido Y.  Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32  Cancer Sci  2007  98(3):438-46  PubMed ID: 17270034   DOI: 10.1111/j.1349-7006.2006.00386.x
3337  Usami, Noriyasu, Fukui, Takayuki, Kondo, Masashi, Taniguchi, Tetsuo, Yokoyama, Toshihiko, Mori, Shoichi, Yokoi, Kohei, Horio, Yoshitsugu, Shimokata, Kaoru, Sekido, Yoshitaka, Hida, Toyoaki  Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients.  Cancer Sci  2006  97:387-94  PubMed ID: 16630136   DOI: 10.1111/j.1349-7006.2006.00184.x

To topTop
User's Publication


Back Back Return Top Page